Table 4 Mean survival time with respect to medical characteristics
Characteristics | Mean survival time in months (95% CI) | p-value (Log Rank) | |
|---|---|---|---|
Baseline CD4 count | ≥ 500 cell/mm3 | 87.3 (77.3–97.4) | 0.001 |
< 500 cell/mm3 | 66.9 (61.3–72.4) | ||
WHO clinical stage | Stage I/II | 64.0 (58.9–69.1) | 0.769 |
Stage III/IV | 62.3 (53.3–71.2) | ||
Retained in care | Yes | 89.7 (65.8–113.5) | 0.057 |
No | 68.7 (64.8–72.6) | ||
Opportunistic infection | Yes | 61.1 (51.1–71.1) | 0.080 |
No | 71.1 (67.0–75.3) | ||
Cotrimoxazole prophylaxis | Yes | 68.2 (64.2–72.1) | 0.351 |
No | 75.6 (59.8–91.4) | ||
Treatment regimen | First linea | 68.6 (64.5–72.7) | 0.346 |
Second lineb | 81.2 (70.2–92.2) | ||
Exposure to cNVP prophylaxis for dPMTCT | Yes | 83.2 (64.2–102.2) | 0.010 |
No | 60.3 (55.4–65.2) | ||
Mode of transmission | Vertical | 69.9 (65.3–74.5) | 0.001 |
Horizontal | 40.2 (23.3–57.0) |